Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pixantrone versus single-agent chemotherapy in relapsed aggressive non-Hodgkin lymphoma
2004-000480-10Phase 3Completed
- Sponsor
- CTI BioPharma
- Start
- Sep 2004
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pixantrone in non-Hodgkin lymphoma (NHL) (2 arms), sponsored by CTI BioPharma. Primary endpoint: Complete response and unconfirmed complete response rate. Started Sep 2004; status: completed.
02
Drugs
pixantrone
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on 2004-000480-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000480-10.